Symmetry-guided design and fluorous synthesis of a stable and rapidly excreted imaging tracer for (19)F MRI.
Ontology highlight
ABSTRACT:
SUBMITTER: Jiang ZX
PROVIDER: S-EPMC2873849 | biostudies-literature | 2009
REPOSITORIES: biostudies-literature
Publications
Symmetry-guided design and fluorous synthesis of a stable and rapidly excreted imaging tracer for (19)F MRI.
Jiang Zhong-Xing ZX Liu Xin X Jeong Eun-Kee EK Yu Yihua Bruce YB
Angewandte Chemie (International ed. in English) 20090101 26
Getting FIT: A bispherical (19)F imaging tracer, (19)FIT, was designed and synthesized. (19)FIT is advantageous over perfluorocarbon-based (19)F imaging agents, as it is not retained in the organs and does not require complex formulation procedures. Imaging agents such as (19)FIT can lead to (19)F magnetic resonance imaging (MRI) playing an important role in drug therapy, analogous to the role played by (1)H MRI in disease diagnosis. ...[more]
Similar Datasets
Project description:Magnetic particle imaging (MPI) uses safe iron oxide nanoparticle tracers to offer fundamentally new capabilities for medical imaging, in applications as vascular imaging and ultra-sensitive cancer therapeutics. MPI is perhaps the first medical imaging platform to intrinsically exploit nanoscale material properties. MPI tracers contain magnetic nanoparticles whose tunable, size-dependent magnetic properties can be optimized by selecting a particular particle size and narrow size-distribution. In this paper we present experimental MPI measurements acquired using a homemade MPI magnetometer: a zero-dimensional MPI imaging system designed to characterize tracer performance by measuring the derivative of the time-varying tracer magnetization, M'(H(t)), at a driving frequency of 25 kHz. We show that MPI performance is optimized by selecting phase-pure magnetite tracers of a particular size and narrow size distribution; in this work, tracers with 20 nm median diameter, log-normal distribution shape parameter, σ(v), equal to 0.26, and hydrodynamic diameter equal to 30 nm showed the best performance. Furthermore, these optimized MPI tracers show 4 × greater signal intensity (measured at the third harmonic) and 20% better spatial resolution compared with commercial nanoparticles developed for MRI.
| S-EPMC3306434 | biostudies-other
Project description:The up-regulation of cell surface receptors has become a central focus in personalized cancer treatment; however, because of the complex nature of contrast agent pharmacokinetics in tumor tissue, methods to quantify receptor binding in vivo remain elusive. Here, we present a dual-tracer optical technique for noninvasive estimation of specific receptor binding in cancer. A multispectral MRI-coupled fluorescence molecular tomography system was used to image the uptake kinetics of two fluorescent tracers injected simultaneously, one tracer targeted to the receptor of interest and the other tracer a nontargeted reference. These dynamic tracer data were then fit to a dual-tracer compartmental model to estimate the density of receptors available for binding in the tissue. Applying this approach to mice with deep-seated gliomas that overexpress the EGF receptor produced an estimate of available receptor density of 2.3 ± 0.5 nM (n = 5), consistent with values estimated in comparative invasive imaging and ex vivo studies.
| S-EPMC3670304 | biostudies-literature
Project description:Rationale: A robust radiopharmaceutical has high uptake in the target and low retention in non-target tissues. However, traditional tracers for renal imaging that chemically chelate 99mTc are excreted through the renal route with transient resident time in the kidney. Following a rational design approach, we constructed a protein-based radiotracer, designated PBT-Fc, to sequentially bind tubular neonatal Fc-receptor and subsequently proximal tubular basement membrane for its targeted sequestration in kidney parenchyma. In this process, the tracer participates in physiologic glomerular filtration and tubular reabsorption while escaping lysosomal catabolism and urinary clearance. Methods: To specifically target renal receptors in navigating the urinary passage in the kidney, we produced a recombinant fusion protein with two separate functional parts: a polybasic PBT segment derived from human Vascular Endothelial Growth Factor and Fc segment of IgG1. The chimeric fusion of PBT-Fc was labeled with radionuclide 99mTc and tested in rodent models of kidney diseases. Planar scintigraphy and single-photon emission computerized tomography (SPECT) were performed to evaluate renal-specificity of the tracer. Results: When injected in mouse and rat, following a brief 10 - 15 min dynamic redistribution phase in circulation, ~ 95% of the [99mTc]-PBT-Fc signal was concentrated in the kidney and lasted for hours without urinary loss or surrounding tissue activities. Long-lasting tracer signals in the kidney cortex in conjunction with SPECT greatly augmented the image quality in detecting pathological lesions in a variety of disease models, including ischemic acute kidney injury, drug-induced renal toxicity, and chronic kidney disease from renin-angiotensin system (RAS) overactivation. Conclusion: Exclusive renal retention of the recombinant radiotracer greatly facilitated static-phase signal acquisition by SPECT and achieved submillimeter spatial resolution of kidney alternations in glomerular and tubular disease models.
| S-EPMC8419037 | biostudies-literature
Project description:Cellular therapeutics are emerging as a treatment option for a host of serious human diseases. To accelerate clinical translation, noninvasive imaging of cell grafts in clinical trials can potentially be used to assess the initial delivery and behavior of cells.The use of a perfluorocarbon (PFC) tracer agent for clinical fluorine-19 ((19) F) MRI cell detection is described. This technology was used to detect immunotherapeutic dendritic cells (DCs) delivered to colorectal adenocarcinoma patients. Autologous DC vaccines were labeled with a PFC MRI agent ex vivo. Patients received DCs intradermally, and (19) F spin-density-weighted MRI at 3 Tesla (T) was used to observe cells.Spin-density-weighted (19) F images at the injection site displayed DCs as background-free "hot-spot" images. (19) F images were acquired in clinically relevant scan times (<10 min). Apparent DC numbers could be quantified in two patients from the (19) F hot-spots and were observed to decrease by ?50% at injection site by 24 h. From 3T phantom studies, the sensitivity limit for DC detection is estimated to be on the order of ?10(5) cells/voxel in this study.These results help to establish a clinically applicable means to track a broad range of cell types used in cell therapy.
| S-EPMC4253123 | biostudies-other
Project description:PurposeTo investigate if imaging biomarkers derived from 3-Tesla dual-tracer [(18)F]fluoromethylcholine (FMC) and [68Ga]Ga-PSMAHBED-CC conjugate 11 (PSMA)-positron emission tomography can adequately predict clinically significant prostate cancer (csPC).MethodsWe assessed 77 biopsy-proven PC patients who underwent 3T dual-tracer PET/mpMRI followed by radical prostatectomy (RP) between 2014 and 2017. We performed a retrospective lesion-based analysis of all cancer foci and compared it to whole-mount histopathology of the RP specimen. The primary aim was to investigate the pretherapeutic role of the imaging biomarkers FMC- and PSMA-maximum standardized uptake values (SUVmax) for the prediction of csPC and to compare it to the mpMRI-methods and PI-RADS score.ResultsOverall, we identified 104 cancer foci, 69 were clinically significant (66.3%) and 35 were clinically insignificant (33.7%). We found that the combined FMC+PSMA SUVmax were the only significant parameters (p < 0.001 and p = 0.049) for the prediction of csPC. ROC analysis showed an AUC for the prediction of csPC of 0.695 for PI-RADS scoring (95% CI 0.591 to 0.786), 0.792 for FMC SUVmax (95% CI 0.696 to 0.869), 0.852 for FMC+PSMA SUVmax (95% CI 0.764 to 0.917), and 0.852 for the multivariable CHAID model (95% CI 0.763 to 0.916). Comparing the AUCs, we found that FMC+PSMA SUVmax and the multivariable model were significantly more accurate for the prediction of csPC compared to PI-RADS scoring (p = 0.0123, p = 0.0253, respectively).ConclusionsCombined FMC+PSMA SUVmax seems to be a reliable parameter for the prediction of csPC and might overcome the limitations of PI-RADS scoring. Further prospective studies are necessary to confirm these promising preliminary results.
| S-EPMC9954891 | biostudies-literature
Project description:MALDI-imaging-guided Transcriptomics
| PRJEB69276 | ENA
Project description:Intraoperative guidance using targeted fluorescent tracers can potentially provide surgeons with real-time feedback on the presence of tumor tissue in resection margins. To overcome the limited depth penetration of fluorescent light, combining fluorescence with SPECT/CT imaging and/or gamma-ray tracing has been proposed. Here, we describe the design and preclinical validation of a novel bimodal nanobody-tracer, labeled using a "multifunctional single attachment point" (MSAP) label, integrating a Cy5 fluorophore and a diethylenetriaminepentaacetic acid (DTPA) chelator into a single structure. After conjugation of the bimodal MSAP to primary amines of the anti-HER2 nanobody 2Rs15d and 111In-labeling of DTPA, the tracer's characteristics were evaluated in vitro. Subsequently, its biodistribution and tumor targeting were assessed by SPECT/CT and fluorescence imaging over 24 h. Finally, the tracer's ability to identify small, disseminated tumor lesions was investigated in mice bearing HER2-overexpressing SKOV3.IP1 peritoneal lesions. [111In]In-MSAP.2Rs15d retained its affinity following conjugation and remained stable for 24 h. In vivo SPECT/CT and fluorescence images showed specific uptake in HER2-overexpressing tumors with low background. High tumor-to-muscle ratios were obtained at 1h p.i. and remained 19-fold on SPECT/CT and 3-fold on fluorescence images over 24 h. In the intraperitoneally disseminated model, the tracer allowed detection of larger lesions via nuclear imaging, while fluorescence enabled accurate removal of submillimeter lesions. Bimodal nuclear/fluorescent nanobody-tracers can thus be conveniently designed by conjugation of a single-molecule MSAP-reagent carrying a fluorophore and chelator for radioactive labeling. Such tracers hold promise for clinical applications.
| S-EPMC7996797 | biostudies-literature
Project description:BackgroundAnaphylaxis represents one of the most severe and fatal forms of allergic reactions. Like most other allergies, it is caused by activation of basophils and mast cells by allergen-mediated cross-linking of IgE bound to its high-affinity receptor, FcεRI, on the cell surface. The systemic release of soluble mediators induces an inflammatory cascade, rapidly causing symptoms with peak severity in minutes to hours after allergen exposure. Primary treatment for anaphylaxis consists of immediate intramuscular administration of adrenaline.ObjectiveWhile adrenaline alleviates life-threatening symptoms of an anaphylactic reaction, there are currently no disease-modifying interventions available. We sought to develop potent and fast-acting IgE inhibitors with the potential to rapidly terminate acute allergic reactions.MethodsUsing affinity maturation by yeast display and structure-guided molecular engineering, we generated 3 optimized disruptive IgE inhibitors based on designed ankyrin repeat proteins and assessed their ability to actively remove IgE from allergic effector cells in vitro as well as in vivo in mice.ResultsThe engineered IgE inhibitors rapidly dissociate preformed IgE:FcεRI complexes, terminate IgE-mediated signaling in preactivated human blood basophils in vitro, and shut down preinitiated allergic reactions and anaphylaxis in mice in vivo.ConclusionsFast-acting disruptive IgE inhibitors demonstrate the feasibility of developing kinetically optimized inhibitors for the treatment of anaphylaxis and the rapid desensitization of allergic individuals.
| S-EPMC8502201 | biostudies-literature
Project description:Multi-tracer positron emission tomography (PET) has the potential to enhance PET imaging by providing complementary information from different physiological processes. However, one or more of the images may present high levels of noise. Guided image reconstruction methods transfer information from a guide image into the PET image reconstruction to encourage edge-preserving noise reduction. In this work we aim to reduce noise in poorer quality PET datasets via guidance from higher quality ones by using a weighted quadratic penalty approach. In particular, we applied this methodology to [18F]fluorodeoxyglucose (FDG) and [11C]methionine imaging of gliomas. 3D simulation studies showed that guiding the reconstruction of methionine datasets using pre-existing FDG images reduced reconstruction errors across the whole-brain (-8%) and within a tumour (-36%) compared to maximum likelihood expectation-maximisation (MLEM). Furthermore, guided reconstruction outperformed a comparable non-local means filter, indicating that regularising during reconstruction is preferable to post-reconstruction approaches. Hyperparameters selected from the 3D simulation study were applied to real data, where it was observed that the proposed FDG-guided methionine reconstruction allows for better edge preservation and noise reduction than standard MLEM. Overall, the results in this work demonstrate that transferring information between datasets in multi-tracer PET studies improves image quality and quantification performance.
| S-EPMC6130802 | biostudies-other
Project description:Standard clinicopathological variables are inadequate for optimal management of prostate cancer patients. While genomic classifiers have improved patient risk classification, the multifocality and heterogeneity of prostate cancer can confound pre-treatment assessment. The objective is to investigate the association of multiparametric (mp)MRI quantitative features with prostate cancer risk gene expression profiles in mpMRI-guided biopsies tissues.
2016-06-07 | GSE80683 | GEO